Prot#LP352-201: A Phase 1b/2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of LP352 in Subjects with Developmental